Previous studies have shown that LOXL2, a member of the lysyl oxidase (LOX) family, not only promotes glioma cell proliferation, migration, and invasion and induces the epithelial-to-mesenchymal transition (EMT) process but also reduces the sensitivity of glioma cells to temozolomide (TMZ) (27). Here, LOX is linked to glioma.